In corticosteroid-treated patients with polymyalgia rheumatica, lumbar spine BMD fell less with salmon calcitonin than with placebo, a significant between-group difference of 3.65 +/- 2.10% (P < 0.05).
In plain wordsIn corticosteroid-treated patients, spine bone density fell less with calcitonin than with placebo.
- Peptide
- Calcitonin-salmon
- Outcome
- IncreaseLumbar spine BMD difference
- Study
n = 31
- Comparator
- placebo
- Analysis
- Primary
- Outcome group
- Bone and joint · Musculoskeletal
- Studied dose
- 200 IU daily · intranasal · 12 monthsAs given in this study (human).
Measurements
- Between-group BMD difference
- 3.65%
- reported result
- Reported uncertainty
- 2.1%
- reported result
- P value
- < 0.05
- reported result
Source sentences
The observed difference of 3.65 +/- 2.10% between groups is statistically significant (P < 0.05).
4 context sentences(design, population, supporting numbers)
The mean +/- S.D. bone mineral density of the lumbar spine in the calcitonin-treated group decreased by 1.29 +/- 6.76% and in the placebo group by 4.95 +/- 3.50% after 12 months.
A minimized, double-blind, placebo-controlled trial was carried out in corticosteroid-treated patients with polymyalgia rheumatica.
The setting was a tertiary care university-affiliated hospital and a total of 31 patients were enrolled.
The primary outcome measure was the percentage change in bone mineral density of the lumbar spine in the two treatment groups from baseline to 1 yr of follow-up.